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Abstract
The effects of the drug delivery system on the PDT activity, localization, and tumor accumulation
of the novel photosensitizer temocene (the porphycene analogue of temoporfin or m-
tetrahydroxyphenyl chlorin) were investigated against the P815 tumor, both in vitro and in DBA/2
tumor bearing mice. Temocene was administered either free (dissolved in PEG400/EtOH mixture),
or encapsulated in Cremophor EL micelles or in DPPC/DMPG liposomes, chosen as model
delivery vehicles. The maximum cell accumulation and photodynamic activity in vitro was
achieved with the free photosensitizer, while temocene in Cremophor micelles hardly entered the
cells. Notwithstanding, the micellar formulation showed the best in vivo response when used in a
vascular regimen (short drug light interval), whereas liposomes were found to be an efficient drug
delivery system for a tumor cell targeting strategy (long drug-light interval). PEG/EtOH
formulation was discarded for further in vivo experiments as it provoked lethal toxic effects
caused by photosensitizer aggregation. These results demonstrate that drug delivery systems
modulate the vascular and cellular outcomes of photodynamic treatments with temocene.
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Photodynamic therapy (PDT) is a tumor treatment modality that uses light, oxygen and a
photosensitizer (PS) for the destruction of targeted tissues [1,2]. These components are
individually non-toxic, but together they generate cytotoxic reactive oxygen species (ROS)
leading to cellular damage [3]. The PS absorbs a photon to form excited states that can
undergo electron transfer (type I reaction) generating superoxide, hydrogen peroxide, and
hydroxyl radicals; or they can instead transfer energy to molecular oxygen to produce highly
cytotoxic singlet oxygen (type II reaction).
There are three main mechanisms that operate to allow PDT to destroy tumors: 1) direct
cellular killing by necrosis and/or apoptosis [4–6], 2) tumor-associated vascular damage
leading to thrombosis and hemorrhage that subsequently cause tumor hypoxia [7–9], and 3)
activation of antitumor immune response contributing to tumor destruction even in distant
locations [10–12]. It is generally accepted that all three mechanisms are necessary for the
optimal tumor damage. The relative contribution of these pathways depends upon the PS
used, the tissue being treated, and treatment conditions. For a particular tissue and PS, the
targeting strategy can be modulated by illumination at a short or long interval after drug
administration, maximizing vascular or cellular targeting, respectively. The PS is
predominantly retained in the tumor vasculature initially after i.v. injection, and light
delivery within minutes after administration damages the tumor vasculature [13]. This
mechanism has received considerably attention in recent years due to the successful clinical
implementation of PDT in age-related macular degeneration treatment with verteporfin [14]
and prostate cancer treatment with Pd-bacteriochlorophyll derivatives TOOKAD and
WST11 [15–17]. Conventional cancer cell targeting approaches allow the PS to freely
diffuse out into the tissue and to accumulate into the tumor cellular compartment. A long
drug-to-light interval generates more direct cytotoxic cellular damage. The selectivity of this
strategy relies on the preferential drug accumulation in the tumor relative to the surrounding
normal tissue.
Thus, pharmacokinetics of the PS plays an important role in effectiveness of both vascular
and cellular PDT. Pharmacokinetics and selectivity can be enhanced by nanoparticles as
vehicles for PS delivery. Different approaches have been developed to enable selective
accumulation of the PS providing an environment where the PS can be administered in
monomeric form and without loss or alteration of its activity [18–21]. Indeed lipid and
detergent nanostructures (liposomes and micelles) have been extensively used in PDT. To
further investigate these questions, we evaluated the influence of different formulations in
PDT effectiveness both in vitro and in vivo. The novel PS temocene [22] was chosen as
photoactive molecule in this study.
Temocene is the porphycene analogue to m-tetrahydroxyphenyl chlorin, commonly named
temoporfin. In a previous work [22], we showed that both the photophysical properties and
photodynamic activity in vitro suggested that temocene was a good candidate for PDT.
These results prompted us to extend our studies to in vivo assays, which required the
development of an effective drug delivery vehicle. Based on the fact that temoporfin is used
clinically either dissolved in a PEG400-EtOH mixture (trade name Foscan®) or formulated
in liposomes (Foslip®), we adopted such vehicles for our studies and included additionally
Cremophor EL micelles as systems of intermediate complexity.
As mentioned above, the targeting strategy is a critical parameter for the success of PDT.
Thus, the effects of drug-to-light interval on tumor regression were also investigated.
Formulations were administered intravenously and PDT was performed 15 min (vascular
targeting) or 24 h (cellular targeting) after injection. We found that Cremophor EL micelles
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The synthesis, molecular characterization and photophysical properties of temocene (Fig.
1A) have been previously described in detail [22]. For cellular and in vivo studies, temocene
was dissolved in PEG400/EtOH (3:2) or formulated in micelles or liposomes as described in
the following sections.
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (DMPG) and 1,2-distearoyl-sn-glycero-3- phosphoethanolamine-
N-[methoxy(polyethylene glycol)-3000] (m-PEG3000-DSPE) were purchased from Avanti
Polar Lipids (Birminghan, AL). 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) and Cremophor EL were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO). MicroBCA protein assay kit was purchased from Pierce Protein Research
Products (Rockford, IL) and used according to the product information sheet. All other
chemicals were commercially available reagents of at least analytical grade.
Micelle preparation
Cremophor micellar solution was prepared by mixing 1 mg of temocene with 2.5 mL of
Cremophor EL solution (100 mg/mL) in dry tetrahydrofuran (THF); 1 mL of THF was
added to this mixture. The final Cremophor/temocene ratio was 250:1 (w/w). The resulting
solution was stirred until it became one phase and isotropic. The solvent was removed by
rotary evaporation. The resulting dry film was completely dissolved in 3 mL of sterile 5%
dextrose solution. The micellar suspension was filtered through 0.22 µm mixed cellulose
ester filter under sterile conditions to remove unloaded temocene. The encapsulation
efficiency was then determined by the ratio of temocene absorbance before and after
filtration. The average size, polydispersity, and zeta potential of the micelles were
determined by photon correlation spectroscopy (PCS). A Zetasizer Nano-ZS (Malvern
Instruments, UK) and a 4 mW He-Ne laser (Spectra Physics), at an excitation wavelength of
633 nm, were used.
Liposome preparation and characterization
Temocene liposomes were prepared by microemulsification following standard procedures
[23,24]. Briefly, DPPC/DMPG/PEG3000-DSPE (67.5:7.5:1 molar ratio) mixture containing
the porphycene at 75:1 lipid/photosensitizer molar ratio was evaporated to dryness from a
dry tetrahydrofuran solution and kept in a vacuum desiccator overnight. Multilamellar
vesicles (MLV) were prepared by hydration of the dried lipid films by vortexing for 30 min
(alternating 30 s periods of heating and 30 s of vortexing) at a concentration of 10 mg lipid/
mL in 10 mM phosphate buffer (pH 7.4) at 60 °C. The MLV dispersion was frozen and
thawed (five times), sonicated (bath sonicator, 15 min, 60 °C) and microemulsified
(EmulsiFlex B3 device, Avestin, Ottawa, Canada). Control liposomes were prepared in the
same way but without the PS.
To enhance stability during storage, liposomes were lyophilized using 5% trehalose as
cryoprotectant agent. 2 mL of liposomal suspension were placed in 4 mL glass vials and
frozen at −80 °C (liquid nitrogen) during 3–5 hours. Vials were subsequently dried during
24 h at −55 °C and 0.04 mbar (Freeze Dryer Alpha 1-2/LD, Martin Christ GmbH,
Germany). Lyophilized liposomes were rehydrated immediately before the experiments by
adding 2 mL of sterile water. The resulting suspension was prewarmed at 60 °C during 15
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min and vortexed for 30 min (alternating 30 s periods of heating/vortexing). The PS and the
lipid content in the liposomes were evaluated before and after lyophilization/rehydration
following standard procedures. Liposomes were disrupted by the addition of DMSO to an
aliquot of the liposomal suspension, free of non-entrapped PS, and the absorbance was
measured at λmax of the Soret band. Lipid content was quantified by a colorimetric assay
with ammonium ferrothiocyanate according to the method of Stewart [25]. The average size,
polydispersity, and zeta potential of the unilamellar vesicles were determined by PCS.
Before measuring, samples were appropriately diluted to avoid multiple scattering.
Cell lines
We used both the DBA/2 mastocytoma cell line P815 (ATCC, TIB-64) [26] and the BALB/c
colon adenocarcinoma cell line CT26.CL25 (ATCC, CRL-2639) that expressed a tumor
antigen, β-galactosidase [27]. Cell lines were cultured in Roswell Park Memorial Institute
(RPMI) medium with L-glutamine and NaHCO3 supplemented with 10% heat inactivated
fetal bovine serum, penicillin (100U/mL) and streptomycin (100 µg/mL) (all from Sigma) at
37 °C in 5% CO2 in 75 cm2 flasks (Falcon, Invitrogen). CT26.CL25 cells were cultured in
constant presence of 500 µg/mL G418 antibiotic in order to maintain constant expression of
the β-galactosidase.
Light source
A Lumacare lamp (Newport Beach, CA) fitted with a light guide and a 640–680 nm band-
pass filter was used. Light guides were adjusted to give a uniform spot with an irradiance of
20 mW/cm2 for in vitro experiments, and 100 mW/cm2 for in vivo treatments. Light power
was measured with a power meter (model DMM 199 with 201 standard head, Coherent,
Santa Clara, CA).
In vitro PDT studies
P815 cells (5,000 cells/well) were plated in flat-bottom 96-well plates (Fisher Scientific,
Pittsburgh, PA). Cells were allowed to attach for 24–48 h. They were then incubated in the
dark with complete RPMI medium containing 0.1–10 µM temocene administered in the
three different formulations. After 18 h incubation, cells were washed three times with PBS,
replenished with fresh medium and 3.5 J/cm2 of illumination were delivered at a fluence rate
of 20 mW/cm2. For time course incubation studies the different formulations were incubated
with P815 cells at 1 µM temocene concentration for various times ranging from 2 to 24 h.
Cells were then washed three times with PBS, replenished with fresh medium and subjected
to 10 J/cm2 PDT treatments. Irradiated cells were then incubated for 24 h and the MTT
assay for cell viability was carried out [28]. Briefly, after washing with PBS, RPMI
containing 0.05 mg/mL MTT was added and incubated for 4 h at 37 °C. The medium was
replaced by DMSO and the absorbance at 550 nm was read on a Spectra Max 340 PC
(Molecular Devices, Sunnyvale, CA) microplate reader. Each experiment was repeated three
times.
Uptake studies
Cells were plated in 6-well plates and allowed to attach for 24–48 h. As described above,
cells were incubated in the dark with complete RPMI medium containing 0.1–10 µM
temocene administered in the three different formulations for 18 h. For time course uptake
studies, cells were incubated with 1 µM temocene for times ranging from 2 to 24 h. Cells
were then washed three times with PBS and disrupted with 0.5 mL of 2% sodium dodecyl
sulfate (SDS) in Milli-Q water. The extent of PS uptake was assessed by comparison of the
fluorescence of this cell lysate to that of standard solutions under the same conditions. The
fluorescence intensity values obtained for each sample were normalized to the number of
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cells determined by the bicinchoninic acid (BCA) protein assay [29]. Each experiment was
repeated twice.
Subcellular localization
Cells were plated in clear flat-bottom 96-well plates and allowed to attach overnight. 1 µM
temocene encapsulated in the three different formulations was added and incubated for 18 h.
Cells were washed in PBS, and 5 µg/mL of (i) LysoTracker green DND-26, (ii) MitoTracker
green FM, or (iii) ER-Tracker green (all from Molecular Probes Invitrogen) were added and
incubated for 30 min at 37 °C. Cells were again washed in PBS and 5–10 min later a
Olympus FV1000, multi-photon confocal microscope was used to image the cells.
Quantification of overlap between organelle probes and the temocene localization were
carried out using image processing and analysis (IPA) software from the public domain
(ImageJ 1.42; http://rsbweb.nih.gov/ij/index.html) [30].
Animal tumor models
DBA/2 and BALB/c mice (6–8 weeks old) were purchased from Charles River Laboratories
(Boston, MA). All experiments were carried out according to a protocol approved by the
Subcommittee on Research Animal Care at (Institutional Animal Care and Use Committee)
at Massachusetts General Hospital and were in accord with guidelines from the National
Institutes of Health (NIH). Mice were inoculated with 350,000 cells subcutaneously into the
depilated left thigh. Two orthogonal dimensions (a and b) of the tumor were measured 3–4
times a week with a vernier caliper. Tumor volumes were calculated as 4π/3 [(a+b)/4]3.
PDT was performed when tumors reached a diameter of 5–7 mm (around 9 days after cell
inoculation).
PDT and tumor response
Tumor bearing mice were anaesthetized with an intraperitoneal injection of 87.5 mg/kg of
ketamine and 12.5 mg/kg xylazine. Temocene (1 mg/kg) formulated in PEG/EtOH solution,
Cremophor micelles or liposomes was administrated intravenously via the tail vein injection.
15 min or 24 h after injection of PS, 660-nm light (Lumacare) was used to irradiate a
homogeneous spot of 1.5 cm diameter that covered the tumor and a margin of normal tissue.
A total fluence of 75 or 150 J/cm2 was delivered at a fluence rate of 100 mW/cm2. The mice
were sacrificed when any of the tumor diameters exceeded 1.5 cm or when any signs of
disseminated metastatic tumor appeared (e.g., >15% loss of body weight).
In vivo fluorescence imaging
Tumor bearing mice were anaesthetized and subsequently placed in the light-tight chamber
of the CRI Maestro (Caliper Life Sciences, Hopkinton, MA) in vivo fluorescence imaging
system [31]. The instrument was set up as follows: images were captured every 10 nm
throughout the wavelength range 650–800 nm using a 488-nm excitation filter, an LP 515-
nm emission filter, and an exposure time of 100 ms. The focus and the stage height were set
manually. Mice were imaged at different time points after temocene tail vein injection. After
the fluorescence image acquisition, the image cubes were unmixed (deconvolved) using a
spectral library containing the autofluorescence of the mice skin and a dilute sample of
temocene in the different vehicles.
Statistics
Unpaired Student’s t test was used to test for the significance level between two sets of
measurements and Kaplan-Meier survival curves were compared with a log-rank test using
GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, CA
www.graphpad.com. The level of significance was set to p <0.05.
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In order to compare the effect of the drug delivery system on PDT efficacy, temocene was
dissolved in PEG400/EtOH (3:2) or formulated in micelles or liposomes. The absorption
spectra of temocene in the different delivery systems are shown in Fig. 1B. Dilution in water
caused aggregation of temocene dissolved in PEG400/EtOH mixture. Temocene incorporated
in Cremophor EL micelles did not show spectral differences compared to THF, so it can be
safely assumed that it is in a monomeric state. The incorporation of temocene into liposomes
produced slight changes in its absorption spectrum, namely an intensity decrease of the
Soret and Q bands. Similar changes have been observed previously for other PS in
liposomes and have been attributed to the ordered lipid environment [24,32].
Table 1 summarizes the main features of the different formulations. The encapsulation
efficiency of both liposomal and micellar formulation was higher than 90%. However,
differences were found regarding the size and the zeta potential. PCS revealed a dynamic
diameter of 30 ± 5 nm for micelles, whereas for liposomes it was 150 ± 20 nm. Likewise,
the electric potential of the particles surface also differed between the formulations.
Specifically, liposomes had a ζpot of −47 ± 2 mV, due to the phosphatidyl group of DMPG,
which gives electrical stability to the colloid formulation. By contrast, Cremophor micelles
had a ζpot close to zero. Despite this fact, the micellar formulation remained stable for
several weeks and no flocculation or aggregation phenomena was observed. In this case, the
thermodynamic stability came from the steric repulsive forces of the polymer-covered
surface. No significant changes in the physicochemical properties were observed after
lyophilization/rehydration of liposomes.
Effect of temocene formulation on PDT effectiveness in vitro
Studies of the effectiveness of the different temocene formulations are summarized in Fig. 2.
P815 cells were incubated in the dark with different concentrations of temocene in the three
formulations, exposed to red light, and assayed for cell survival. In the in vitro experiments,
cells were incubated with different concentrations of temocene during 18 h. There was no
dark toxicity in case of liposomal formulation at any of the concentrations tested, whereas
the PEG/EtOH solutions showed substantial dark toxicity at high concentrations (Fig. 2A).
In the presence of light, both formulations showed PDT-induced loss of mitochondrial
activity in a concentration-, light dose- and incubation time-dependent manner (Fig. 2B, 2C
and 2D), the PEG/EtOH solution being the most effective at the same concentration and
light dose. Interestingly, no PDT effect could be observed with micelles, which showed the
same extent of cell kill in the dark as upon delivery of a 3.5 or 10 J/cm2 light dose. These
results are consistent with the uptake studies (Fig. 2E) since minimal internalization was
observed with the micellar formulation. Specifically, temocene internalization at 24 h was
minimum for micelles, maximum for PEG/EtOH, and liposomes showing an intermediate
behavior. Notwithstanding the lower uptake, it is worth noting that liposomes are the most
effective vehicle when the photodynamic activity is compared on a per-molecule-cell uptake
basis (Fig. 2F).
Subcellular localization
Confocal microscopy was used to examine the intracellular localization of temocene taken
up after delivery by the different systems. For these studies the formulations were co-
incubated with green-fluorescent probes specific for mitochondria (MitoTracker), lysosomes
(LysoTracker) and endoplasmic reticulum (ER-Tracker). The overlaid images and the
fluorescent topographic profiles are shown in Fig. 3. The stained patterns of the
mitochondrial probe and temocene were different regardless of the formulation, indicating
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marginal accumulation of the PS in the mitochondria. The fluorescent profile of temocene
perfectly matched with the green fluorescence of the lysosomal probe for all formulations.
In the case of ER probe, the overlapping was partial. It is important to note that it was
necessary to use a higher exposure time for the micrographs of cells incubated with
Cremophor micelles due to the limited internalization. No morphological changes were
detected in the cells under these conditions and no relocalization of the PS was observed
when cells were exposed to confocal excitation light.
Effect of temocene formulation on tumor accumulation in vivo
Temocene incorporated in PEG/EtOH, micelles or liposomes was injected intravenously
through the tail vein in a dose of 1 mg/kg in tumor bearing mice. Temocene dissolved in
PEG/EtOH induced death of all mice immediately after injection because of aggregation of
PS in the blood stream that provoked the collapse of lungs and kidneys (see Supplementary
data for histology studies). We checked that this toxicity was not due to PEG/EtOH mixture
alone (no temocene). The PEG/EtOH formulation was consequently discarded for in vivo
experiments. The tumor accumulation of temocene incorporated in micelles or liposomes
was studied by non-invasive methods using a Maestro in vivo fluorescence camera system.
Non-invasive fluorescence imaging provides a fast and convenient method to qualitatively
compare the photosensitizer tumor accumulation profile when it is administered in different
vehicles. Since the fluorescence quantum yield of temocene is different in liposomes and in
micelles (data not shown), the fluorescence intensity of temocene could not be strictly
comparable and only the tumor accumulation profile as function of time after i.v.
administration was analyzed. The results are shown in Fig. 4. The pharmacokinetics of
tumor uptake was influenced by the drug delivery system. Liposomal temocene showed a
maximum in fluorescence intensity 24 h after injection. In the case of the micellar
formulation, the fluorescence reached its highest intensity 8 h after injection. A high tumor-
to-normal tissue ratio for a PS is considered to be important in PDT to ensure the maximum
selectivity of the treatment and minimal normal tissue damage. Liposomes showed a better
tumor selectivity, accumulating in the tumor three-times higher than in the surrounding skin.
It is important to note that no significant effect on tumor growth was observed after drug
injection (no light, dark control) as compared to absolute control mice (no light and no
drug).
Effect of temocene formulation and targeting strategy on PDT effectiveness in vivo
Tumor bearing mice were divided into the following groups and each group included 8–10
animals: (i) control groups: dark control (no light), light control (no drug), absolute control
(no light and no drug); (ii) vascular response group: mice treated with 150 J/cm2 15 min
after i.v. injection of 1 mg/kg liposomal or micellar temocene; (iii) cellular response group:
mice treated with 150 J/cm2 24 h after i.v. injection of 1 mg/kg liposomal or micellar
temocene.
Mean tumor volumes plot and Kaplan-Meier survival analysis are shown in Fig. 5. In all
cases, PDT produced a local response in P815-treated tumors, as manifested by an acute
inflammation and edema in the first 24 h after treatment followed by tumor necrosis and a
dark eschar formation over the area formerly occupied by the tumor. Subsequently a marked
reduction in tumor size was observed. Animals were observed for up to 60 days after
treatment for metastasis development, tumor regrowth and tissue healing. No significant
differences in survival or tumor volume progress were observed between the different
control groups so we only plotted absolute controls for the sake of clarity. The combined
therapy of micellar formulation with short drug-to-light interval was clearly the most
effective combination. This group resulted in a total regression of the principal tumor and
stayed in remission for the whole course of observation (Fig. 5A). It is important to note that
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although P815 grew as localized subcutaneous tumors, they also metastasized to draining
lymph nodes and liver fairly early in the course of disease (Supplementary Fig. S3E–F) so
the complete regression of principal tumor does not consequently imply the animal survival.
In this case, temocene encapsulated in micelles resulted in a delay or even avoidance (3 out
of 8 mice) of mice death (Fig. 5C). The vascular PDT regime using the liposomal
formulation of temocene was not highly effective resulting in a local tumor regrowth
relatively quickly. In marked contrast was the cellular targeting strategy (Fig. 5B and 5D).
Liposomal treatment led to a delay of tumor regrowth and a significant survival advantage.
PDT performed 24 hours after injection of temocene in Cremophor micelles had no effect in
terms of survival compared to controls and local tumor regrew few days after treatment.
Treatments were also tested in a BALB/c mouse tumor model. CT26.CL25 tumor cells were
inoculated subcutaneously in the left thigh and the same treatments were performed, namely
1 mg/kg temocene in micellar or liposomal formulation, and 150 J/cm2 of light dose at 15
min or 24 h after injection. Under these conditions, all treatments worked perfectly resulting
in a total tumor regression 4 days after PDT performance. Only when the light dose was
reduced to 75 J/cm2 (Supplementary Fig. S4) we obtained a differential response.
Liposomes in a short drug-to-light interval were not effective and the tumor volume
evolution was similar to control group.
Discussion
The mechanisms of action for PDT are complex, depending upon the PS, light dosimetry,
drug delivery system, and treatment conditions. Temocene (m-tetrahydroxyphenyl
porphycene) is a novel promising PS whose photophysical properties and in vitro PDT
efficacy in DMSO were recently studied [22]. However, the inherent unsuitability of DMSO
prompted us to consider formulating temocene in different drug delivery systems. The
formulation of a PS plays an important role in its activity by modulating the
pharmacokinetics, uptake, and subcellular distribution and localization. The present study
investigated the effect of three different vehicles, namely PEG400/EtOH solutions,
Cremophor micelles, and DPPC/DMPG/PEG3000-DSPE liposomes, on the PDT
effectiveness of temocene.
Micelles, prepared by film formation and hydration just before experiments, and liposomes,
prepared by microemulsification and then lyophilized to guarantee a long-term stability
during all the experimental stage, allowed for a high encapsulation of temocene in a
monomeric state. Aggregation of the PS was evident when delivered in PEG400/EtOH
solution. In spite of this fact, this formulation showed the best in vitro response because cells
were able to internalize the largest amount of PS. However, the killing efficacy per uptaken
molecule was higher in the case of liposomes. A minimal internalization and, therefore, no
photocytotoxic effect were observed with the micellar formulation. Attempts to modify this
situation by removing serum or diluting beyond the critical micellar concentration proved
unsuccessful. No redistribution effects were observed in presence of serum indicating that
temocene remained entrapped in micelles during cell incubation (Supplementary Fig. S1). A
literature search revealed that in some circumstances intact micelles are hardly taken up by
cells [33–35]. It should be noted that Cremophor EL would not be a suitable micellar
formulation to be used for clinical applications. Cremophor EL is known to induce a pseudo-
allergic reaction by activation of the complement system [36], even though the mice in this
study showed no ill-effects of Cremophor EL micelle administration. Alternative micellar
formulations such as poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone)
triblock copolymers [37] could be studied that would have less risk of toxicity.
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Regarding the subcellular localization of temocene internalized in the different drug delivery
systems, in vitro experiments performed with organelle-specific fluorescent probes revealed
no difference between the vehicles. In all cases, lysosomes were the preferential site of
temocene accumulation in P815 cells. These results differed from those obtained in a
previous work in HeLa cells, where temocene preferentially localized in mitochondria [22].
However, in that work temocene had been delivered in DMSO, which is a membrane
permeabilizer [38], whereas the drug delivery systems used in the current experiments
internalize drugs mainly by endocytosis, which is characterized by the formation of
endocytic vacuoles (lysosome progenitors) [39, 40].
Drug delivery systems can also modulate in vivo pharmacokinetics and tumor accumulation.
P815 tumor bearing mice were studied by non-invasive methods at different times after i.v.
injection of the different formulations. Although temocene in PEG/EtOH solution could be
considered a promising formulation based on its good in vitro response, the formulation
failed when it was administered intravenously causing the immediate death of the mice due
to aggregation of the PS in the blood stream. In vivo fluorescence imaging studies
demonstrated that there was no specific tumor accumulation of temocene after 15 min. On
the other hand, the kinetics of tumor uptake with the liposomal formulation showed the
highest tumor extravasation 24 h after injection. Micelles showed a faster tumor
accumulation that can be explained by the rapid clearance of micelles by reticuloendothelial
system. Pegylated liposomes exhibit steric stabilization and avoid reticuloendothelial system
uptake, resulting in prolonged circulation times and enhanced selective localization. The
accumulation of macromolecules in tumors is mainly due to the so-called enhanced
permeability and retention effect and this progressive phenomenon can be greatly favored by
prolonging the half-life in plasma of nanoparticles [20,41,42]. This effect is also dependent
of the size of nanoparticles: small carriers can diffuse in and out of the tumor blood vessels
because of their small size, and, hence, the effective concentration of the drug in the tumor
diminishes compared to larger vehicles [43]. Thus, the difference of size between temocene
loaded micelles (30 nm) and liposomes (180 nm) can also affect the kinetics of drug
accumulation in the tumor. Liposomes also showed the best tumor selectivity, namely a
tumor-to-normal-tissue ratio of 3.
The time between PS administration and light treatment is also a critical parameter for PDT
efficiency. The best PDT response was obtained when light irradiation was delivered 15 min
after micelle-loaded temocene injection. This treatment led to an acute inflammatory
reaction as evidenced by a large amount of edema in the treated leg, which resulted in total
regression of the primary tumor with extended survival. Vascular perfusion results also
demonstrate that the major target for the 15 min interval micellar PDT treatment is tumor
vasculature causing the disruption of functional blood vessels (Supplementary Fig. S5). In a
cellular-targeted regimen, liposomal temocene exhibited the best PDT response. Tumor
regrowth was delayed, although not fully prevented, and mouse survival was improved. In
this case, micelles were not effective. These results agree with the 3-fold higher tumor
accumulation of the PS attained by liposomes relative to Cremophor micelles.
These results were also corroborated using the BALB/c mouse model tumor. Delivery of the
same light and drug doses used in the P815 tumor experiments (150 J/cm2, 1 mg/kg
temocene) caused a total regression of tumor in all cases. Only when the light dose was
halved (75 J/cm2), the vascular response of liposomal formulation had no effect in terms of
tumor volume diminution and the advantage of the micellar formulation could be
appreciated (Supplementary Fig. S4).
To summarize our findings, we have confirmed that both the drug delivery system chosen
and the targeting strategy employed can determine the PDT effectiveness of the new PS
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temocene both in vitro and in vivo. It is important to mention that in vitro tests not always
reproduce in vivo results. Micelles showed no PDT activity in cell cultures while they were
the most effective formulation for in vivo PDT treatments combined with a short drug-to-
light interval. This of course reflects that this formulation targets the tumor vasculature,
which in vitro cultures lack. In contrast, temocene in PEG/EtOH solutions could have been
regarded as a good vehicle based on the in vitro results but caused immediate toxicity when
they were administered intravenously. Liposomes are the best vehicle in terms of achieving
cell internalization and tumor selectivity. In conclusion, we have shown that PDT with the
novel PS temocene has significant therapeutic effects in a metastatic tumor model, both for a
vascular-targeted treatment with its Cremophor EL formulation, and also for a cellular
strategy when it is encapsulated in DPPC/DMPG/PEG3000-DSPE liposomes.
Supplementary Material
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A) Chemical structure of temocene. B) Absorption of 2.5 µM temocene in aqueous
suspensions of different drug delivery systems: liposomes (black solid line), micelles
(dashed line), PEG/EtOH (dotted line). Absorption of temocene dissolved in THF (blue
solid line) is shown for comparison.
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In vitro PDT effectiveness of temocene dissolved in PEG/EtOH (triangles) or encapsulated
in micelles (squares) or liposomes (circles). A) Dark toxicity after 18 h incubation in P815
cell line. B) Effectiveness of 3.5 J/cm2 after 18 h incubation. C) Light dose dependence after
18 h incubation. D) Effectiveness of 10 J/cm2 after different incubation times. E) Cellular
uptake by P815 cells. F). PDT effectiveness after 10 J/cm2 per unit uptake.
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Fluorescence micrographs of P815 cells showing red fluorescence from temocene in
different formulations overlaid with green fluorescence from lysotracker, mitotracker or ER-
tracker. Fluorescent topographic profiles of cells are showed under confocal images. Arrow
indicates the analyzed longitudinal transcellular zone.
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Tumor accumulation of temocene incorporated in micelles or liposomes after i.v. injection.
A) Series of in vivo fluorescence images of temocene encapsulated in liposomes
accumulated in P815 tumor. B) Fluorescence intensity of temocene in P815 tumor at
different times after i.v. injection (the intensities have been normalized to facilitate
comparison of their time profile). C) Tumor-to-normal tissue ratio calculated by the fraction
of the fluorescence intensity in the tumor and the fluorescence intensity in the surrounding
skin. Data show the mean ± SD of three mice.
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Panels A and B) Plots of mean tumor volumes in mice bearing P815 tumor. Points are
means of 8–10 tumors and bars are SD. Panels C and D) Kaplan-Meier survival curves of %
mice cured from P815 tumors. Vascular response: PDT performed 15 min after i.v. injection
of 1 mg/kg formulated temocene. Cellular response: PDT performed 24 h after i.v. injection
of 1 mg/kg formulated temocene. Light dose: 150 J/cm2
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Table 1
Physicochemical characteristics of the different formulations as measured by PS and lipid content, particle
size and zeta potential.
Formulation %PSa %Lb Zave/nmc ζpot/mVd
Micelles 95 ± 2 n.a. 30 ± 5 −1.5 ± 0.5
Liposomes 90 ± 3 85 ± 5 150 ± 20 −47 ± 2
Liposomes after
lyophilization/rehydration
90 ± 5 90 ± 5 180 ± 20 −55 ± 5
Data are mean values ± SD of at least three independent experiments.
a
%PS: Encapsulation efficiency expressed as the percentage of PS in the sample with respect to the PS present at the initial stage of preparation.
b
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